PhRMA white paper on ADME pharmacogenomics

Journal of Clinical Pharmacology

Volumn 48, Issue 7, 2008, Pages 849-889

  Williams, J Andrew ^a,n   Andersson, Tommy ^c   Andersson, Tommy B ^c,d   Blanchard, Rebecca ^f   Behm, Martin Otto ^f   Cohen, Nadine ^g   Edeki, Timi ^e   Franc, Monique ^g   Hillgren, Kathleen M ^h   Johnson, Keith J ^b   Katz, David A ⁱ   Milton, Mark N ^j,m   Murray, Bernard P ^i,l   Polli, Joseph W ^k   Ricci, Deb ^g   Shipley, Lisa A ^h   Vangala, Subrahmanyam ^g,n   Wrighton, Steven A ^h  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b AstraZeneca R and D Mölndal ^*

^c KAROLINSKA INSTITUTE   (Sweden)

^d ASTRAZENECA   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h ABBOTT LABORATORIES   (United States)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

^j GLAXOSMITHKLINE   (United States)

^k GILEAD SCIENCES   (United States)

^l Tempo Pharmaceuticals   (United States)

^m Sai Advantium Pharma Ltd   (India)

ⁿ PFIZER INC   (United States)

more..

Author keywords

ADME; Drug metabolizing enzymes; Genotyping; Pharmacogenomics; PhRMA

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANTINEOPLASTIC AGENT; ATOMOXETINE; ATRASENTAN; CENTRAL NERVOUS SYSTEM AGENTS; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE M1; LAMOTRIGINE; LIDOCAINE; LOSARTAN; MERCAPTOPURINE; METHYLXANTHINE DERIVATIVE; MEXILETINE; MUSCLE RELAXANT AGENT; OLANZAPINE; PHENACETIN; PIMOBENDAN; REPAGLINIDE; RIFAMPICIN; RILUZOLE; THIOPURINE METHYLTRANSFERASE; THIORIDAZINE; TIPIFARNIB; TRANILAST; UNINDEXED DRUG; ZIPRASIDONE;

BONE MARROW SUPPRESSION; CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG SAFETY; DRUG UTILIZATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GILBERT DISEASE; GLUCURONIDATION; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERBILIRUBINEMIA; MAJOR DEPRESSION; PHARMACOGENOMICS; PRACTICE GUIDELINE; QT PROLONGATION; QUALITY CONTROL; RESTENOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARD; UNITED STATES;

ARYLSULFOTRANSFERASE; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INDUSTRY; DRUG INTERACTIONS; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 45749146622     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008319329     Document Type: Review

References (343)

1. Spear B., Heath-Chiozzi M., Barnes D., et al. Terminology for sample collection in clinical genetic studies. Pharmacogenomics. 2001 ; 2: 317-327.
2. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 ; 353: 717-719.
3. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003 ; 31: 98-107.
4. Sauer JM, Ring BJ, Witcher JW Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005 ; 44: 571-590.
5. Michelson D., Faries D., Wernicke J., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001 ; 108: E83.
6. Spencer T., Heiligenstein JH, Biederman J., et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 ; 63: 1140-1147.
7. Allen AJ, Wernicke JF, Dunn D., et al. Safety and efficacy of atomoxetine in pediatric CYP2D6 extensive and poor metabolizers. Biol Psychiatry. 2001 ; 49: 37S.
8. Wernicke JF, Kratochvil CJ Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002 ; 63: 50-55.
9. Niemi M., Leathart JB, Neuvonen M., et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003 ; 74: 380-387.
10. Kajosaari LI, Niemi M., Backman JT, et al. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther. 2006 ; 79: 231-242.
11. Peterkin VC, Bauman JN, Goosen TC, et al. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol. 2007 ; 64: 458-468.
12. Zhang D., Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005 ; 33: 1729-1739.
13. Xu CF, Lewis KF, Yeo AJ, et al. Identification of a pharmacogenetic effect by linkage disequilibrium mapping. Pharmacogenomics J. 2004 ; 4: 374-378.
14. Danoff TM, Campbell DA, McCarthy LC, et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilastinduced hyperbilirubinemia. Pharmacogenomics J. 2004 ; 4: 49-53.
15. Murphy MP, Beaman ME, Clark LS, et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. Pharmacogenetics. 2000 ; 10: 583-590.
16. Perez-Ruixo JJ, Zannikos P., Ozdemir V., et al. Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib. Cancer Chemother Pharmacol. 2006 ; 58: 681-691.
17. Katz DA, Carr R., Grimm DR, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 ; 79: 186-196.
18. McCrea JB, Cribb A., Rushmore T., et al. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther. 1999 ; 65: 348-352.
19. Furman KD, Grimm DR, Mueller T., et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics. 2004 ; 14: 279-284.
20. Myrand SP, Sekiguchi K., Man M., et al. Pharmacokinetics/ genotype associations for major cytochrome P450 enzymes in native, first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008 ;[Epub ahead of print].
21. Piotrovsky V., Van PA, Van ON, et al. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. J Clin Pharmacol. 2003 ; 43: 514-523.
22. Thompson JF, Man M., Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005 ; 5: 352-358.
23. Katz DA, Grimm DR, Cassar SC, et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther. 2004 ; 75: 516-528.
24. von BC, Movin G., Nordin C., et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther. 1991 ; 49: 234-240.
25. Hartigan-Go K., Bateman DN, Nyberg G., et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996 ; 60: 543-553.
26. Lennard L., Van Loon JA, Lilleyman JS, et al. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther. 1987 ; 41: 18-25.
27. Innocenti F., Undevia SD, Iyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 ; 22: 1382-1388.
28. Toffoli G., Cecchin E., Corona G., et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006 ; 24: 3061-3068.
29. Hoskins JM, Goldberg RM, Qu P., et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007 ; 99: 1290-1295.
30. Marsh S. Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther. 2007 ; 11: 79-82.
31. O'Dwyer PJ, Catalano RB Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006 ; 24: 4534-4538.
32. Furuta T., Ohashi K., Kamata T., et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998 ; 129: 1027-1030.
33. Furuta T., Shirai N., Takashima M., et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics. 2001 ; 11: 341-348.
34. Tanigawara Y., Aoyama N., Kita T., et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther. 1999 ; 66: 528-534.
35. Katz DA, Murray B., Bhathena A., et al. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov. 2008 ; 7: 293-305.
36. Renegar G., Webster CJ, Stuerzebecher S., et al. Returning genetic research results to individuals: points-to-consider. Bioethics. 2006 ; 20: 24-36.
37. Corchero J., Pimprale S., Kimura S., et al. Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics. 2001 ; 11: 1-6.
38. Landi MT, Sinha R., Lang NP, et al. Human cytochrome P4501A2. IARC Sci Pub. 1999 ; 148: 173-195.
39. Pineau T., Fernandez-Salguero P., Lee SS, et al. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci USA. 1995 ; 92: 5134-5138.
40. Liang HC, Li H., McKinnon RA, et al. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. Proc Natl Acad Sci USA. 1996 ; 93: 1671-1676.
41. Mise M., Hashizume T., Matsumoto S., et al. Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics. 2004 ; 14: 769-773.
42. Tenmizu D., Endo Y., Noguchi K., et al. Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion. Xenobiotica. 2004 ; 34: 835-846.
43. Rasmussen BB, Brix TH, Kyvik KO, et al. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics. 2002 ; 12: 473-478.
44. Miller CA, Slusher LB, Vesell ES Polymorphism of theophylline metabolism in man. J Clin Invest. 1985 ; 75: 1415-1425.
45. Minchin RF, McManus ME, Boobis AR, et al. Polymorphic metabolism of the carcinogen 2-acetylaminofluorene in human liver microsomes. Carcinogenesis. 1985 ; 6: 1721-1724.
46. Sesardic D., Boobis AR, Edwards RJ, et al. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol. 1988 ; 26: 363-372.
47. Nakajima M., Yokoi T., Mizutani M., et al. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev. 1994 ; 3: 413-421.
48. Welfare MR, Aitkin M., Bassendine MF, et al. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics. 1999 ; 9: 367-375.
49. Nakajima M., Yokoi T., Mizutani M., et al. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem. 1999 ; 125: 803-808.
50. Aklillu E., Carrillo JA, Makonnen E., et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003 ; 64: 659-669.
51. Chen X., Wang L., Zhi L., et al. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther. 2005 ; 78: 249-259.
52. Sachse C., Brockmoller J., Bauer S., et al. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999 ; 47: 445-449.
53. Ghotbi R., Christensen M., Roh HK, et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007 ; 63: 537-546.
54. Takata K., Saruwatari J., Nakada N., et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharmacol. 2006 ; 62: 23-28.
55. Ozdemir V., Kalow W., Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C→A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001 ; 21: 603-607.
56. Eap CB, Bender S., Jaquenoud SE, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004 ; 24: 214-219.
57. Iwasaki M., Yoshimura Y., Asahi S., et al. Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population. Drug Metab Pharmacokinet. 2004 ; 19: 444-452.
58. Solus JF, Arietta BJ, Harris JR, et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004 ; 5: 895-931.
59. Zhou H., Josephy PD, Kim D., et al. Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch Biochem Biophys. 2004 ; 422: 23-30.
60. Murayama N., Soyama A., Saito Y., et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther. 2004 ; 308: 300-306.
61. Saito Y., Hanioka N., Maekawa K., et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos. 2005 ; 33: 1905-1910.
62. Jiang Z., Dragin N., Jorge-Nebert LF, et al. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics. 2006 ; 16: 359-367.
63. van der Weide J., Steijns LS, van Weelden MJ The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003 ; 13: 169-172.
64. Sachse C., Bhambra U., Smith G., et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol. 2003 ; 55: 68-76.
65. Hoffman SM, Fernandez-Salguero P., Gonzalez FJ, et al. Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J Mol Evol. 1995 ; 41: 894-900.
66. Ekins S., Wrighton SA The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev. 1999 ; 31: 719-754.
67. Braybrooke JP, Slade A., Deplanque G., et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res. 2005 ; 11: 1512-1520.
68. Turpeinen M., Tolonen A., Uusitalo J., et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005 ; 77: 553-559.
69. Kirchheiner J., Klein C., Meineke I., et al. Bupropion and 4-OHbupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 ; 13: 619-626.
70. Rae JM, Soukhova NV, Flockhart DA, et al. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos. 2002 ; 30: 525-530.
71. Pascussi JM, Gerbal-Chaloin S., Drocourt L., et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003 ; 1619: 243-253.
72. Zukunft J., Lang T., Richter T., et al. A natural CYP2B6 TATA box polymorphism (-82T→C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol. 2005 ; 67: 1772-1782.
73. Bumpus NN, Sridar C., Kent UM, et al. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos. 2005 ; 33: 795-802.
74. Rotger M., Saumoy M., Zhang K., et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics. 2007 ; 17: 885-890.
75. Nakajima M., Komagata S., Fujiki Y., et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics. 2007 ; 17: 431-445.
76. Tsuchiya K., Gatanaga H., Tachikawa N., et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004 ; 319: 1322-1326.
77. Rotger M., Colombo S., Furrer H., et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005 ; 15: 1-5.
78. Hasse B., Gunthard HF, Bleiber G., et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis. 2005 ; 40: e22 - e23.
79. Desta Z., Saussele T., Ward B., et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007 ; 8: 547-558.
80. Rodriguez-Novoa S., Barreiro P., Rendon A., et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005 ; 40: 1358-1361.
81. Rotger M., Tegude H., Colombo S., et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007 ; 81: 557-566.
82. Gatanaga H., Hayashida T., Tsuchiya K., et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007 ; 45: 1230-1237.
83. Wang J., Sonnerborg A., Rane A., et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006 ; 16: 191-198.
84. Klein K., Lang T., Saussele T., et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics. 2005 ; 15: 861-873.
85. Mehlotra RK, Ziats MN, Bockarie MJ, et al. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol. 2006 ; 62: 267-275.
86. Wrighton SA, Stevens JC The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992 ; 22: 1-21.
87. Goldstein JA, de Morais SM Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994 ; 4: 285-299.
88. Shimada T., Yamazaki H., Mimura M., et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994 ; 270: 414-423.
89. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004 ; 25: 193-200.
90. Totah RA, Rettie AE Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther. 2005 ; 77: 341-352.
91. Andersson T., Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol. 1993 ; 36: 521-530.
92. Li XQ, Bjorkman A., Andersson TB, et al. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 ; 300: 399-407.
93. Ding X., Kaminsky LS Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003 ; 43: 149-173.
94. Yasar U., Lundgren S., Eliasson E., et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun. 2002 ; 299: 25-28.
95. Ahmadi KR, Weale ME, Xue ZY, et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet. 2005 ; 37: 84-89.
96. Veenstra DL, Blough DK, Higashi MK, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther. 2005 ; 77: 353-364.
97. Dai D., Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001 ; 11: 597-607.
98. Soyama A., Hanioka N., Saito Y., et al. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol Toxicol. 2002 ; 91: 174-178.
99. Garcia-Martin E., Martinez C., Tabares B., et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004 ; 76: 119-127.
100. Stubbins MJ, Harries LW, Smith G., et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996 ; 6: 429-439.
101. Yasar U., Eliasson E., Dahl ML, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999 ; 254: 628-631.
102. Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002 ; 54: 1257-1270.
103. Imai J., Ieiri I., Mamiya K., et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics. 2000 ; 10: 85-89.
104. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001 ; 60: 382-387.
105. Blaisdell J., Jorge-Nebert LF, Coulter S., et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 ; 14: 527-537.
106. Kidd RS, Curry TB, Gallagher S., et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 ; 11: 803-808.
107. DeLozier TC, Lee SC, Coulter SJ, et al. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 ; 315: 1085-1090.
108. Yamazaki H., Inoue K., Chiba K., et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol. 1998 ; 56: 243-251.
109. Takanashi K., Tainaka H., Kobayashi K., et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 2000 ; 10: 95-104.
110. Kirchheiner J., Roots I., Goldammer M., et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005 ; 44: 1209-1225.
111. Kirchheiner J., Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005 ; 77: 1-16.
112. Martinez C., Blanco G., Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004 ; 141: 205-208.
113. Holstein A., Plaschke A., Ptak M., et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005 ; 60: 103-106.
114. Daly AK, King BP Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003 ; 13: 247-252.
115. Scordo MG, Pengo V., Spina E., et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002 ; 72: 702-710.
116. Bodin L., Verstuyft C., Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 ; 106: 135-140.
117. Geisen C., Watzka M., Sittinger K., et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005 ; 94: 773-779.
118. Allabi AC, Horsmans Y., Issaoui B., et al. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West black African population. Eur J Clin Pharmacol. 2005 ; 61: 97-102.
119. Kupfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984 ; 26: 753-759.
120. Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys. 1993 ; 306: 240-245.
121. Goldstein JA, Faletto MB, Romkes-Sparks M., et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994 ; 33: 1743-1752.
122. Meier UT, Meyer UA Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase: studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry. 1987 ; 26: 8466-8474.
123. Blaisdell J., Mohrenweiser H., Jackson J., et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 2002 ; 12: 703-711.
124. Desta Z., Zhao X., Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002 ; 41: 913-958.
125. Inaba T., Jorge LF, Arias TD Mephenytoin hydroxylation in the Cuna Amerindians of Panama. Br J Clin Pharmacol. 1988 ; 25: 75-79.
126. Kaneko A., Kaneko O., Taleo G., et al. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet. 1997 ; 349: 921-922.
127. Venkatakrishnan K., Greenblatt DJ, Von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998 ; 38: 112-121.
128. Nielsen KK, Flinois JP, Beaune P., et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996 ; 277: 1659-1664.
129. Koyama E., Chiba K., Tani M., et al. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 ; 281: 1199-1210.
130. Eap CB, Bender S., Gastpar M., et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP. Ther Drug Monit. 2000 ; 22: 209-214.
131. Fukuda T., Yamamoto I., Nishida Y., et al. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999 ; 47: 450-453.
132. Koyama E., Tanaka T., Chiba K., et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol. 1996 ; 16: 286-293.
133. Morinobu S., Tanaka T., Kawakatsu S., et al. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci. 1997 ; 51: 253-257.
134. Kirchheiner J., Brosen K., Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001 ; 104: 173-192.
135. Wang JH, Liu ZQ, Wang W., et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 ; 70: 42-47.
136. Liu ZQ, Cheng ZN, Huang SL, et al. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol. 2001 ; 52: 96-99.
137. Sindrup SH, Brosen K., Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993 ; 15: 11-17.
138. Knodell RG, Dubey RK, Wilkinson GR, et al. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther. 1988 ; 245: 845-849.
139. Nakamura K., Goto F., Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 ; 38: 402-408.
140. Daniel HI, Edeki TI Genetic polymorphism of S-mephenytoin 4'-hydroxylation. Psychopharmacol Bull. 1996 ; 32: 219-230.
141. Ieiri I., Mamiya K., Urae A., et al. Stereoselective 4'- hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br J Clin Pharmacol. 1997 ; 43: 441-445.
142. Kaminsky LS, de Morais SM, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol. 1993 ; 43: 234-239.
143. Skjelbo E., Mutabingwa TK, Bygbjerg I., et al. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther. 1996 ; 59: 304-311.
144. Bertilsson L., Henthorn TK, Sanz E., et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989 ; 45: 348-355.
145. Andersson T., Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol. 1994 ; 38: 131-137.
146. Caraco Y., Tateishi T., Wood AJ Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther. 1995 ; 58: 62-72.
147. Furuta T., Shirai N., Watanabe F., et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002 ; 72: 453-460.
148. Kuwayama H., Luk G., Yoshida S., et al. Efficacy of a low-dose omeprazole-based triple-therapy regimen for Helicobacter pylori eradication independent of cytochrome P450 genotype: the Japanese MACH study. Clin Drug Investig. 2005 ; 25: 293-305.
149. Ibeanu GC, Blaisdell J., Ghanayem BI, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics. 1998 ; 8: 129-135.
150. Goldstein JA, Ishizaki T., Chiba K., et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997 ; 7: 59-64.
151. Ishizaki T., Sohn DR, Kobayashi K., et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit. 1994 ; 16: 214-215.
152. Andersson T., Holmberg J., Rohss K., et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol. 1998 ; 45: 369-375.
153. Sim SC, Risinger C., Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006 ; 79: 103-113.
154. Kurzawski M., Gawronska-Szklarz B., Wrzesniewska J., et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol. 2006 ; 62: 877-880.
155. Rudberg I., Mohebi B., Hermann M., et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2007 ; 83: 322-327.
156. Schroth W., Antoniadou L., Fritz P., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007 ; 25: 5187-5193.
157. Zanger UM, Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004 ; 369: 23-37.
158. Yu AM, Idle JR, Gonzalez FJ Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev. 2004 ; 36: 243-277.
159. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005 ; 5: 6-13.
160. Kimura S., Umeno M., Skoda RC, et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989 ; 45: 889-904.
161. Edeki TI, He H., Wood AJ Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA. 1995 ; 274: 1611-1613.
162. Johansson I., Lundqvist E., Bertilsson L., et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993 ; 90: 11825-11829.
163. Andersson T., Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005 ; 78: 559-581.
164. Bernard S., Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006 ; 11: 126-135.
165. Raimundo S., Fischer J., Eichelbaum M., et al. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics. 2000 ; 10: 577-581.
166. Janicki PK, Schuler HG, Jarzembowski TM, et al. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Anesth Analg. 2006 ; 102: 1127-1133.
167. Fux R., Morike K., Prohmer AM, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther. 2005 ; 78: 378-387.
168. Gardiner SJ, Begg EJ Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice ? Pharmacogenet Genomics. 2005 ; 15: 365-369.
169. Mulder H., Wilmink FW, Beumer TL, et al. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. J Clin Psychopharmacol. 2005 ; 25: 188-191.
170. Gaedigk A., Ndjountche L., Divakaran K., et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007 ; 81: 242-251.
171. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit. 2004 ; 26: 192-199.
172. Wrighton SA, Thummel KE CYP3A. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, eds. Metabolic Drug Interactions. Philadelphia: Lippincott-Raven; 2000.
173. Wilkinson GR Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 1996 ; 24: 475-490.
174. Benet LZ, Kroetz DL, Sheiner LB Pharmacokinetics. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996.
175. Wrighton SA, Schuetz EG, Thummel KE, et al. The human CYP3A subfamily: practical considerations. Drug Metab Rev. 2000 ; 32: 339-361.
176. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 ; 30: 883-891.
177. Wrighton SA, Ring BJ, Watkins PB, et al. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol. 1989 ; 36: 97-105.
178. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001 ; 27: 383-391.
179. Wrighton SA, VandenBranden M. Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. Arch Biochem Biophys. 1989 ; 268: 144-151.
180. Smit P., van Schaik RH, van der WM, et al. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab. 2005 ; 90: 5313-5316.
181. Westlind A., Malmebo S., Johansson I., et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun. 2001 ; 281: 1349-1355.
182. Backman JT, Kivisto KT, Olkkola KT, et al. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998 ; 54: 53-58.
183. Ozdemir V., Kalow W., Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000 ; 10: 373-388.
184. Daly AK Pharmacogenetics of the cytochromes P450. Curr Top Med Chem. 2004 ; 4: 1733-1744.
185. Flockhart DA, Rae JM Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J. 2003 ; 3: 3-5.
186. He P., Court MH, Greenblatt DJ, et al. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther. 2005 ; 77: 373-387.
187. Ingelman-Sundberg M., Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci. 2005 ; 360: 1563-1570.
188. Hustert E., Haberl M., Burk O., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001 ; 11: 773-779.
189. Thummel KE Does the CYP3A5*3 polymorphism affect in vivo drug elimination ? Pharmacogenetics. 2003 ; 13: 585-587.
190. Zhao Y., Song M., Guan D., et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc. 2005 ; 37: 178-181.
191. Malaiyandi V., Sellers EM, Tyndale RF Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005 ; 77: 145-158.
192. Vuilleumier N., Rossier MF, Chiappe A., et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006 ; 62: 423-429.
193. Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol. 2006 ; 46: 65-100.
194. Koukouritaki SB, Hines RN Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics. 2005 ; 6: 807-822.
195. Hisamuddin IM, Wehbi MA, Chao A., et al. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res. 2004 ; 10: 8357-8362.
196. Coulthard SA, Hall AG Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J. 2001 ; 1: 254-261.
197. Weinshilboum R., Raftogianis R. Sulfotransferases and Methyltransferases. In: Levy R, ed. Metabolic Drug Interactions. Philadelphia: Lippincott-Raven ; 2000.
198. Szumlanski C., Otterness D., Her C., et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996 ; 15: 17-30.
199. Krynetski EY, Fessing MY, Yates CR, et al. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. Pharm Res. 1997 ; 14: 1672-1678.
200. Lee D., Szumlanski C., Houtman J., et al. Thiopurine methyltransferase pharmacogenetics: cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos. 1995 ; 23: 398-405.
201. Weinshilboum RM, Otterness DM, Szumlanski CL Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol. 1999 ; 39: 19-52.
202. Weinshilboum RM, Sladek SL Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 ; 32: 651-662.
203. Schaeffeler E., Eichelbaum M., Reinisch W., et al. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22): association with decreased enzyme function. Hum Mutat. 2006 ; 27: 976.
204. Lindqvist M., Skoglund K., Karlgren A., et al. Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23. Pharmacogenet Genomics. 2007 ; 17: 891-895.
205. Spire-Vayron de la Moureyre C., Debuysere H., Mastain B., et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol. 1998 ; 125: 879-887.
206. Yan L., Zhang S., Eiff B., et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther. 2000 ; 68: 210-219.
207. Gisbert JP, Gomollon F., Cara C., et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci. 2007 ; 52: 1262-1269.
208. Krynetski EY, Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA. 1995 ; 92: 949-953.
209. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996 ; 58: 694-702.
210. Otterness D., Szumlanski C., Lennard L., et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997 ; 62: 60-73.
211. Otterness DM, Szumlanski CL, Wood TC, et al. Human thiopurine methyltransferase pharmacogenetics: kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest. 1998 ; 101: 1036-1044.
212. Hon YY, Fessing MY, Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet. 1999 ; 8: 371-376.
213. Spire-Vayron de la Moureyre C., Debuysere H., Sabbagh N., et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat. 1998 ; 12: 177-185.
214. Tai HL, Krynetski EY, Schuetz EG, et al. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA. 1997 ; 94: 6444-6449.
215. Lennard L., Van Loon JA, Weinshilboum RM Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989 ; 46: 149-154.
216. Lennard L., Lilleyman JS, Van LJ, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 ; 336: 225-229.
217. Evans WE, Horner M., Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase- deficient child with acute lymphocytic leukemia. J Pediatr. 1991 ; 119: 985-989.
218. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001 ; 29: 601-605.
219. Evans WE, Hon YY, Bomgaars L., et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001 ; 19: 2293-2301.
220. Kaskas BA, Louis E., Hindorf U., et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut. 2003 ; 52: 140-142.
221. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999 ; 91: 2001-2008.
222. Lewis LD, Benin A., Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997 ; 62: 464-475.
223. Lennard L., Lewis IJ, Michelagnoli M., et al. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies. Med Pediatr Oncol. 1997 ; 29: 252-255.
224. Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol. 2000 ; 42: 628-632.
225. Tan BB, Lear JT, Gawkrodger DJ, et al. Azathioprine in dermatology: a survey of current practice in the U.K. Br J Dermatol. 1997 ; 136: 351-355.
226. Tenhunen J., Salminen M., Lundstrom K., et al. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem. 1994 ; 223: 1049-1059.
227. Grunhaus L., Ebstein R., Belmaker R., et al. A twin study of human red blood cell catechol-o-methyl transferase. Br J Psychiatry. 1976 ; 128: 494-498.
228. Spielman RS, Weinshilboum RM Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet. 1981 ; 10: 279-290.
229. Weinshilboum RM, Raymond FA, Elveback LR, et al. Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. Nature. 1974 ; 252: 490-491.
230. Weinshilboum RM, Raymond FA Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet. 1977 ; 29: 125-135.
231. Gershon ES, Jonas WZ Erythrocyte soluble catechol-O-methyl transferase activity in primary affective disorder: a clinical and genetic study. Arch Gen Psychiatry. 1975 ; 32: 1351-1356.
232. Lachman HM, Papolos DF, Saito T., et al. Human catechol-O- methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996 ; 6: 243-250.
233. Kunugi H., Nanko S., Ueki A., et al. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci Lett. 1997 ; 221: 202-204.
234. Li T., Vallada H., Curtis D., et al. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics. 1997 ; 7: 349-353.
235. McLeod HL, Fang L., Luo X., et al. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther. 1994 ; 270: 26-29.
236. Lotta T., Vidgren J., Tilgmann C., et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995 ; 34: 4202-4210.
237. Dawling S., Roodi N., Mernaugh RL, et al. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 2001 ; 61: 6716-6722.
238. Shield AJ, Thomae BA, Eckloff BW, et al. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry. 2004 ; 9: 151-160.
239. Srivastava V., Varma PG, Prasad S., et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics. 2006 ; 16: 111-117.
240. Dauvilliers Y., Neidhart E., Billiard M., et al. Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J. 2002 ; 2: 65-68.
241. Weinshilboum RM, Otterness DM, Aksoy IA, et al. Sulfation and sulfotransferases 1: sulfotransferase molecular biology: cDNAs and genes. FASEB J. 1997 ; 11: 3-14.
242. Blanchard RL, Freimuth RR, Buck J., et al. A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics. 2004 ; 14: 199-211.
243. Falany CN Enzymology of human cytosolic sulfotransferases. FASEB J. 1997 ; 11: 206-216.
244. Falany CN, Xie X., Wang J., et al. Molecular cloning and expression of novel sulphotransferase-like cDNAs from human and rat brain. Biochem J. 2000 ; 346: 857-864.
245. Her C., Kaur GP, Athwal RS, et al. Human sulfotransferase SULT1C1: cDNA cloning, tissue-specific expression, and chromosomal localization. Genomics. 1997 ; 41: 467-470.
246. Fujita K., Nagata K., Ozawa S., et al. Molecular cloning and characterization of rat ST1B1 and human ST1B2 cDNAs, encoding thyroid hormone sulfotransferases. J Biochem. 1997 ; 122: 1052-1061.
247. Sakakibara Y., Yanagisawa K., Katafuchi J., et al. Molecular cloning, expression, and characterization of novel human SULT1C sulfotransferases that catalyze the sulfonation of N-hydroxy-2-acetylaminofluorene. J Biol Chem. 1998 ; 273: 33929-33935.
248. Walther S., Dunbrack R., Raftogianis R. Molecular and biochemical characterization of human SULT4A1, a novel sulfotransferase. Drug Metab Rev. 2000 ; 32: 36.
249. Nowell S., Falany CN Pharmacogenetics of human cytosolic sulfotransferases. Oncogene. 2006 ; 25: 1673-1678.
250. Hildebrandt MA, Carrington DP, Thomae BA, et al. Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J. 2007 ; 7: 133-143.
251. Campbell NR, Van Loon JA, Weinshilboum RM Human liver phenol sulfotransferase: assay conditions, biochemical properties and partial purification of isozymes of the thermostable form. Biochem Pharmacol. 1987 ; 36: 1435-1446.
252. Campbell N., Weinshilboum R. Human phenol sulfotransferase (PST): correlation of liver and platelet activities. Can Soc Clin Invest. 1986 ; 9: A14.
253. Price RA, Spielman RS, Lucena AL, et al. Genetic polymorphism for human platelet thermostable phenol sulfotransferase (TS PST) activity. Genetics. 1989 ; 122: 905-914.
254. Raftogianis RB, Wood TC, Otterness DM, et al. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun. 1997 ; 239: 298-304.
255. Raftogianis RB, Wood TC, Weinshilboum RM Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol. 1999 ; 58: 605-616.
256. Coughtrie MW, Gilissen RA, Shek B., et al. Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J. 1999 ; 337: 45-49.
257. Carlini EJ, Raftogianis RB, Wood TC, et al. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics. 2001 ; 11: 57-68.
258. Ozawa S., Shimizu M., Katoh T., et al. Sulfating-activity and stability of cDNA-expressed allozymes of human phenol sulfotransferase, ST1A3*1 ((213)Arg) and ST1A3*2 ((213)His), both of which exist in Japanese as well as Caucasians. J Biochem. 1999 ; 126: 271-277.
259. Nagar S., Walther S., Blanchard RL Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol. 2006 ; 69: 2084-2092.
260. Nowell S., Sweeney C., Winters M., et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst. 2002 ; 94: 1635-1640.
261. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 ; 97: 30-39.
262. Blum M., Grant DM, McBride W., et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990 ; 9: 193-203.
263. Grant DM, Blum M., Demierre A., et al. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res. 1989 ; 17: 3978.
264. Butcher NJ, Boukouvala S., Sim E., et al. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2002 ; 2: 30-42.
265. Bonicke R., Reif W. [Enzymatic inactivation of isonicotinic acid hydrizide in human and animal organism.]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1953 ; 220: 321-323.
266. Bosch TM, Meijerman I., Beijnen JH, et al. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet. 2006 ; 45: 253-285.
267. Innocenti F., Iyer L., Ratain MJ Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 2001 ; 29: 596-600.
268. Innocenti F. UGT1A1 genotyping in patients undergoing treatment with irinotecan. Clin Adv Hematol Oncol. 2005 ; 3: 843-844.
269. Strassburg CP, Nguyen N., Manns MP, et al. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol. 1998 ; 54: 647-654.
270. Bosma PJ, van der Meer IM, Bakker CT, et al. UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem. 2003 ; 49: 1180-1181.
271. Beutler E., Gelbart T., Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism ? Proc Natl Acad Sci USA. 1998 ; 95: 8170-8174.
272. Kadakol A., Ghosh SS, Sappal BS, et al. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat. 2000 ; 16: 297-306.
273. Esteban A., Perez-Mateo M. Heterogeneity of paracetamol metabolism in Gilbert's syndrome. Eur J Drug Metab Pharmacokinet. 1999 ; 24: 9-13.
274. Iyer L., Das S., Janisch L., et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002 ; 2: 43-47.
275. Mathijssen RH, Marsh S., Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003 ; 9: 3246-3253.
276. Paoluzzi L., Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol. 2004 ; 44: 854-860.
277. Sai K., Saeki M., Saito Y., et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004 ; 75: 501-515.
278. Carlini LE, Meropol NJ, Bever J., et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 ; 11: 1226-1236.
279. Riedy M., Wang JY, Miller AP, et al. Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmacogenetics. 2000 ; 10: 251-260.
280. Saeki Y., Sakakibara Y., Araki Y., et al. Molecular cloning, expression, and characterization of a novel mouse liver SULT1B1 sulfotransferase. J Biochem. 1998 ; 124: 55-64.
281. Hirota T., Ieiri I., Takane H., et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos. 2003 ; 31: 677-680.
282. Holthe M., Rakvag TN, Klepstad P., et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 2003 ; 3: 17-26.
283. Bolt HM, Thier R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab. 2006 ; 7: 613-628.
284. Dean M., Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr. 2001 ; 33: 475-479.
285. Dantzig AH, Hillgren K., de Alwis DP Drug transporters and their role in tissue distribution. Annu Rep Med Chem. 2004 ; 39: 279-291.
286. Dean M. The Human ATP-Binding (ABC) Transporter Superfamily. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mono_001.chapter.137
287. Dallas S., Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006 ; 58: 140-161.
288. Breedveld P., Beijnen JH, Schellens JH Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci. 2006 ; 27: 17-24.
289. Raub TJ P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm. 2006 ; 3: 3-25.
290. Krishnamurthy P., Schuetz JD Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol. 2006 ; 46: 381-410.
291. Mao Q., Unadkat JD Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 ; 7: E118 - E133.
292. Choudhuri S., Klaassen CD Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol. 2006 ; 25: 231-259.
293. Ho RH, Kim RB Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005 ; 78: 260-277.
294. Marzolini C., Paus E., Buclin T., et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 ; 75: 13-33.
295. Leschziner GD, Andrew T., Pirmohamed M., et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007 ; 7: 154-179.
296. Pauli-Magnus C., Kroetz DL Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res. 2004 ; 21: 904-913.
297. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 ; 234: 4-33.
298. Wang D., Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005 ; 15: 693-704.
299. Kim KA, Park PW, Park JY Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol. 2007 ; 63: 53-58.
300. Mealey KL, Bentjen SA, Gay JM, et al. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. 2001 ; 11: 727-733.
301. Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectininduced neurotoxicity. Toxicol Appl Pharmacol. 1997 ; 143: 357-365.
302. Hirouchi M., Suzuki H., Itoda M., et al. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res. 2004 ; 21: 742-748.
303. Meier Y., Pauli-Magnus C., Zanger UM, et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology. 2006 ; 44: 62-74.
304. Hulot JS, Villard E., Maguy A., et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics. 2005 ; 15: 277-285.
305. Rau T., Erney B., Gores R., et al. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006 ; 80: 468-476.
306. Niemi M., Schaeffeler E., Lang T., et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004 ; 14: 429-440.
307. Niemi M., Arnold KA, Backman JT, et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics. 2006 ; 16: 801-808.
308. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007 ; 81: 42-49.
309. Ishikawa T., Tamura A., Saito H., et al. Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Naturwissenschaften. 2005 ; 92: 451-463.
310. Zhang W., Yu BN, He YJ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta. 2006 ; 373: 99-103.
311. Sparreboom A., Gelderblom H., Marsh S., et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther. 2004 ; 76: 38-44.
312. Zhou Q., Sparreboom A., Tan EH, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol. 2005 ; 59: 415-424.
313. Sadee W., Graul RC, Lee AY Classification of membrane transporters. Pharm Biotechnol. 1999 ; 12: 29-58.
314. Koepsell H., Endou H. The SLC22 drug transporter family. Pflugers Arch. 2004 ; 447: 666-676.
315. Wright SH Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol. 2005 ; 204: 309-319.
316. Fujita T., Urban TJ, Leabman MK, et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci. 2006 ; 95: 25-36.
317. Anzai N., Kanai Y., Endou H. Organic anion transporter family: current knowledge. J Pharmacol Sci. 2006 ; 100: 411-426.
318. Sweet DH Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol. 2005 ; 204: 198-215.
319. Hagenbuch B., Meier PJ Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/ functional properties. Pflugers Arch. 2004 ; 447: 653-665.
320. Marzolini C., Tirona RG, Kim RB Pharmacogenomics of the OATP and OAT families. Pharmacogenomics. 2004 ; 5: 273-282.
321. Neuvonen PJ, Niemi M., Backman JT Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 ; 80: 565-581.
322. Daniel H., Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 2004 ; 447: 610-618.
323. Zhang EY, Emerick RM, Pak YA, et al. Comparison of human and monkey peptide transporters: PEPT1 and PEPT2. Mol Pharm. 2004 ; 1: 201-210.
324. Konig J., Seithel A., Gradhand U., et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006 ; 372: 432-443.
325. Nishizato Y., Ieiri I., Suzuki H., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003 ; 73: 554-565.
326. Mwinyi J., Johne A., Bauer S., et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004 ; 75: 415-421.
327. Niemi M., Neuvonen PJ, Hofmann U., et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics. 2005 ; 15: 303-309.
328. Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005 ; 78: 342-350.
329. Niemi M., Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 ; 77: 468-478.
330. Zhang W., He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol. 2006 ; 62: 567-572.
331. Niemi M., Kivisto KT, Hofmann U., et al. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol. 2005 ; 59: 602-604.
332. Zhang EY, Fu DJ, Pak YA, et al. Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: implications for the functional role of Pro586. J Pharmacol Exp Ther. 2004 ; 310: 437-445.
333. Anderle P., Nielsen CU, Pinsonneault J., et al. Genetic variants of the human dipeptide transporter PEPT1. J Pharmacol Exp Ther. 2006 ; 316: 636-646.
334. Pinsonneault J., Nielsen CU, Sadee W. Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther. 2004 ; 311: 1088-1096.
335. Bhatnagar V., Xu G., Hamilton BA, et al. Analyses of 5′regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3). J Hum Genet. 2006 ; 51: 575-580.
336. Xu G., Bhatnagar V., Wen G., et al. Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int. 2005 ; 68: 1491-1499.
337. Shu Y., Leabman MK, Feng B., et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA. 2003 ; 100: 5902-5907.
338. Leabman MK, Huang CC, Kawamoto M., et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002 ; 12: 395-405.
339. Kerb R., Brinkmann U., Chatskaia N., et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002 ; 12: 591-595.
340. Shu Y., Sheardown SA, Brown C., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007 ; 117: 1422-1431.
341. Clayton TA, Lindon JC, Cloarec O., et al. Pharmacometabonomic phenotyping and personalized drug treatment. Nature. 2006 ; 440: 1073-1077.
342. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology. 2002 ; 181-182: 447-452.
343. Daly AK Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003 ; 17: 27-41.